MA71624A - Dégradation de protéine ciblée de parp14 pour une utilisation en thérapie - Google Patents
Dégradation de protéine ciblée de parp14 pour une utilisation en thérapieInfo
- Publication number
- MA71624A MA71624A MA71624A MA71624A MA71624A MA 71624 A MA71624 A MA 71624A MA 71624 A MA71624 A MA 71624A MA 71624 A MA71624 A MA 71624A MA 71624 A MA71624 A MA 71624A
- Authority
- MA
- Morocco
- Prior art keywords
- parp14
- therapy
- protein degradation
- targeted protein
- targeted
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263393522P | 2022-07-29 | 2022-07-29 | |
| US202263420307P | 2022-10-28 | 2022-10-28 | |
| US202363443170P | 2023-02-03 | 2023-02-03 | |
| PCT/US2023/028955 WO2024026081A1 (fr) | 2022-07-29 | 2023-07-28 | Dégradation de protéine ciblée de parp14 pour une utilisation en thérapie |
| EP23758760.5A EP4561999A1 (fr) | 2022-07-29 | 2023-07-28 | Dégradation de protéine ciblée de parp14 pour une utilisation en thérapie |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA71624A true MA71624A (fr) | 2025-05-30 |
Family
ID=87797850
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA71624A MA71624A (fr) | 2022-07-29 | 2023-07-28 | Dégradation de protéine ciblée de parp14 pour une utilisation en thérapie |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20240101540A1 (fr) |
| EP (1) | EP4561999A1 (fr) |
| JP (1) | JP2025526433A (fr) |
| KR (1) | KR20250055509A (fr) |
| CN (1) | CN119923391A (fr) |
| AU (1) | AU2023312809A1 (fr) |
| CA (1) | CA3262703A1 (fr) |
| CO (1) | CO2025002261A2 (fr) |
| IL (1) | IL318518A (fr) |
| MA (1) | MA71624A (fr) |
| MX (1) | MX2025001060A (fr) |
| TW (1) | TW202417435A (fr) |
| WO (1) | WO2024026081A1 (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202508568A (zh) | 2023-04-07 | 2025-03-01 | 瑞典商阿斯特捷利康公司 | Irak4蛋白水解靶向嵌合體 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017197056A1 (fr) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Dégronimères ciblant un bromodomaine pour la dégradation de protéines cibles |
| WO2019126443A1 (fr) | 2017-12-21 | 2019-06-27 | Ribon Therapeutics Inc. | Quinazolinones en tant qu'inhibiteurs de parp14 |
| AU2019251151B2 (en) * | 2018-04-09 | 2022-07-07 | Shanghaitech University | Target protein degradation compounds, their anti-tumor use, their intermediates and use of intermediates |
| JP2022537349A (ja) | 2019-06-19 | 2022-08-25 | ライボン・セラピューティクス・インコーポレイテッド | 療法に使用するためのparp14の標的タンパク質分解 |
-
2023
- 2023-07-28 CN CN202380067993.1A patent/CN119923391A/zh active Pending
- 2023-07-28 AU AU2023312809A patent/AU2023312809A1/en active Pending
- 2023-07-28 WO PCT/US2023/028955 patent/WO2024026081A1/fr not_active Ceased
- 2023-07-28 IL IL318518A patent/IL318518A/en unknown
- 2023-07-28 US US18/227,639 patent/US20240101540A1/en active Pending
- 2023-07-28 EP EP23758760.5A patent/EP4561999A1/fr active Pending
- 2023-07-28 TW TW112128351A patent/TW202417435A/zh unknown
- 2023-07-28 JP JP2025504663A patent/JP2025526433A/ja active Pending
- 2023-07-28 MA MA71624A patent/MA71624A/fr unknown
- 2023-07-28 KR KR1020257002994A patent/KR20250055509A/ko active Pending
- 2023-07-28 CA CA3262703A patent/CA3262703A1/fr active Pending
-
2025
- 2025-01-27 MX MX2025001060A patent/MX2025001060A/es unknown
- 2025-02-27 CO CONC2025/0002261A patent/CO2025002261A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20250055509A (ko) | 2025-04-24 |
| IL318518A (en) | 2025-03-01 |
| CN119923391A (zh) | 2025-05-02 |
| CA3262703A1 (fr) | 2024-02-01 |
| AU2023312809A1 (en) | 2025-02-06 |
| US20240101540A1 (en) | 2024-03-28 |
| EP4561999A1 (fr) | 2025-06-04 |
| JP2025526433A (ja) | 2025-08-13 |
| CO2025002261A2 (es) | 2025-03-27 |
| MX2025001060A (es) | 2025-05-02 |
| WO2024026081A1 (fr) | 2024-02-01 |
| TW202417435A (zh) | 2024-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA56513A (fr) | Dégradation de protéine ciblée de parp14 pour une utilisation en thérapie | |
| MA55511A (fr) | Inhibiteurs de protéine tyrosine phosphatase | |
| PT3990005T (pt) | Cistationina beta-sintetase peguilada para terapia enzimática para tratamento de homocistinúria | |
| MA71624A (fr) | Dégradation de protéine ciblée de parp14 pour une utilisation en thérapie | |
| PL3999119T3 (pl) | Modyfikowane białka kapsydu aav do leczenia choroby zapalnej stawów | |
| EP4221715A4 (fr) | Thérapie anti-inflammatoire périvasculaire pour thrombose veineuse | |
| EP4067495A4 (fr) | Construction d'arnm pour l'expression de protéines et utilisation associées | |
| EP4497062A4 (fr) | Prédiction de branche dépendante de la charge | |
| IL307902A (en) | Microdystrophin gene therapy administration for treatment of dystrophinopathies | |
| EP4004024A4 (fr) | Domaines protéiques multimères pour la multifonctionnalité et la sécrétion améliorée de protéines thérapeutiques | |
| JP1778652S (ja) | マッサージ器 | |
| MA71618A (fr) | Dégradation de protéine ciblée de parp14 pour une utilisation en thérapie | |
| EP3923911A4 (fr) | Utilisation de compositions topiques d'inhibiteur de braf pour le traitement d'une radiodermatite | |
| IL308290A (en) | Ionic liquid formulations for treating inflammatory and autoimmune diseases | |
| EP4313117A4 (fr) | Utilisation de polypeptides adnf en thérapie | |
| EP4282874A4 (fr) | Peptide pour prévenir et traiter la fibrose | |
| PL4034661T3 (pl) | Wektory aav typu „wszystko w jednym” do leczenia chorób wywołanych koronawirusem | |
| EP4003290C0 (fr) | Stabilisation de protéines thérapeutiques avec des substances zwittérioniques de mise en mémoire tampon contenant de la pipérazine ou de la morpholine | |
| EP4251757A4 (fr) | Expression fondée sur une levure de protéines thérapeutiques in vivo | |
| EP3807306A4 (fr) | Séquence leader pour une expression plus élevée de protéines recombinées | |
| PL4482481T3 (pl) | Związki do zastosowania w leczeniu dystrofinopatii | |
| EP4188433A4 (fr) | Administration ciblée d'agents thérapeutiques | |
| EP4463167A4 (fr) | Ciblage de xkr8 dans des thérapies | |
| HK40127146A (en) | Targeted protein degradation of parp14 for use in therapy | |
| HK40127147A (en) | Targeted protein degradation of parp14 for use in therapy |